Market capitalization | $10.81m |
Enterprise Value | $-1.71m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.02 |
EV/Sales (TTM) EV/Sales | -1.80 |
P/S ratio (TTM) P/S ratio | 11.38 |
P/B ratio (TTM) P/B ratio | 0.61 |
Revenue growth (TTM) Revenue growth | -95.23% |
Revenue (TTM) Revenue | $950.00k |
As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.
1 Analyst has issued a forecast Affimed N.V.:
1 Analyst has issued a forecast Affimed N.V.:
Sep '24 |
+/-
%
|
||
Revenue | 0.95 0.95 |
95%
95%
|
|
Gross Profit | - - |
-
|
|
EBITDA | -76 -76 |
38%
38%
|
EBIT (Operating Income) EBIT | -80 -80 |
36%
36%
|
Net Profit | -76 -76 |
40%
40%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Affimed NV engages in discovering and developing of targeted cancer immunotherapies. Its pipelines include Innate Cell Engagers and T Cell Engagers. The company was founded in 2000 and is headquartered in Heidelberg, Germany.
Head office | Netherlands |
CEO | Shawn Leland |
Founded | 2000 |
Website | www.affimed.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.